Journal article icon

Journal article

Anti-Tumour Necrosis Factor therapy for Dupuytren’s disease: a randomised dose response proof of concept phase 2a clinical trial

Abstract:

Background: Dupuytren’s disease is a common fibrotic condition of the hand that causes irreversible flexion contractures of the fingers, with no approved therapy for early stage disease. Our previous analysis of surgically-excised tissue defined tumour necrosis factor (TNF) as a potential therapeutic target...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.ebiom.2018.06.022

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS; KIR
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS; KIR
Davidson, D More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS; KIR
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS; CSM
Expand authors...
Health Innovation Challenge Fund More from this funder
Publisher:
Elsevier Publisher's website
Journal:
EBioMedicine Journal website
Volume:
33
Pages:
282–288
Publication date:
2018-07-05
Acceptance date:
2018-06-19
DOI:
ISSN:
2352-3964
Pubs id:
pubs:858408
URN:
uri:825bd252-3f7b-4756-8c50-42848cdfd780
UUID:
uuid:825bd252-3f7b-4756-8c50-42848cdfd780
Local pid:
pubs:858408

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP